NeuroPace (NPCE) said Monday that Medicare reimbursement will "substantially increase" for its RNS neurostimulator implant and replacement procedures.

The physician fee schedule for 2026 increases professional payment for neurosurgeons by about 43% for the initial implant and 45% for replacement procedures, the company said.

Separately, the outpatient prospective payment system final rule increases average hospital medicare reimbursement by 47% starting Jan. 1, 2026.

Shares of NeuroPace were up by 2% in recent Monday premarket activity.